Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 5/20 | 0.54 |
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | IGF2R | P11717 | 4/20 | 0.38 |
| ▸ | FGF1 | P05230 | 2/20 | 0.35 |
| ▸ | FGF2 | P09038 | 2/20 | 0.35 |
| ▸ | VEGFA | P15692 | 2/20 | 0.35 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670685 | 0.95 | GJB2 (0.54) | GJB2GBA1TNFMAPK1IGF2R | |
| SCHEMBL2670689 | 0.95 | GJB2 (0.54) | GJB2GBA1TNFMAPK1IGF2R | |
| SCHEMBL9926368 | 0.95 | GJB2 (0.50) | GJB2GBA1TNFSMN1; SMN2MAPK1 | |
| SCHEMBL9926358 | 0.95 | GJB2 (0.50) | GJB2GBA1TNFSMN1; SMN2MAPK1 | |
| SCHEMBL1342242 | 0.91 | GBA1 (0.51) | GJB2GBA1TNFMAPK1IGF2R | |
| SCHEMBL17976782 | 0.91 | GJB2 (0.52) | GJB2GBA1TNFSMN1; SMN2MAPK1 | |
| SCHEMBL19644571 | 0.91 | GJB2 (0.52) | GJB2GBA1TNFSMN1; SMN2MAPK1 | |
| SCHEMBL17359603 | 0.91 | GJB2 (0.52) | GJB2GBA1TNFSMN1; SMN2MAPK1 | |
| SCHEMBL12924474 | 0.91 | GJB2 (0.52) | GJB2GBA1TNFSMN1; SMN2MAPK1 | |
| SCHEMBL15948696 | 0.91 | GJB2 (0.52) | GJB2GBA1TNFSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225246-A1 | O-acetyl-ADP-ribose non-hydrolyzable analogs | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225246-A1 | O-acetyl-ADP-ribose non-hydrolyzable analogs | PARP1, TIPARP, CD38 | GJB2 4884/4885GBA1 1556/4885TNF 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.